SADR Gengle™ - a Database Inheriting Google® Technology in Presenting Genes Responsible for Serious Adverse Drug Reactions

Search Where =

Cholestasis



Pathway Foreground Gene Count & Ratio Background Gene Count & Ratio p-value q-value
Cellular antigens 107 / 19.31% 480 / 5.98% 2.23E-24 3.54E-22
Cytokine-cytokine receptor interaction 75 / 13.54% 275 / 3.42% 2.27E-21 1.73E-19
Prostate cancer 45 / 8.12% 90 / 1.12% 3.26E-21 1.73E-19
Toll-like receptor signaling pathway 44 / 7.94% 103 / 1.28% 1.07E-18 4.25E-17
Pancreatic cancer 37 / 6.68% 69 / 0.86% 2.11E-18 6.70E-17
Type I diabetes mellitus 30 / 5.42% 44 / 0.55% 2.94E-17 7.80E-16
Colorectal cancer 37 / 6.68% 86 / 1.07% 5.59E-16 1.27E-14
MAPK signaling pathway 64 / 11.55% 277 / 3.45% 2.62E-15 5.21E-14
Chronic myeloid leukemia 33 / 5.96% 72 / 0.90% 5.30E-15 9.36E-14
Glioma 30 / 5.42% 64 / 0.80% 5.96E-14 9.48E-13
Non-small cell lung cancer 27 / 4.87% 53 / 0.66% 2.39E-13 3.26E-12
Focal adhesion 50 / 9.03% 199 / 2.48% 2.46E-13 3.26E-12
Adipocytokine signaling pathway 28 / 5.05% 68 / 0.85% 5.00E-12 6.12E-11
Apoptosis 31 / 5.60% 88 / 1.10% 9.52E-12 1.08E-10
Bladder cancer 22 / 3.97% 40 / 0.50% 1.30E-11 1.38E-10
Endometrial cancer 24 / 4.33% 51 / 0.63% 1.91E-11 1.90E-10
Natural killer cell mediated cytotoxicity 38 / 6.86% 142 / 1.77% 4.35E-11 4.07E-10
Melanoma 27 / 4.87% 71 / 0.88% 5.24E-11 4.63E-10
Renal cell carcinoma 26 / 4.69% 67 / 0.83% 8.38E-11 6.73E-10
Small cell lung cancer 29 / 5.23% 85 / 1.06% 8.46E-11 6.73E-10
Metabolism of xenobiotics by cytochrome P450 26 / 4.69% 70 / 0.87% 1.82E-10 1.35E-09
Cytokines 48 / 8.66% 229 / 2.85% 1.87E-10 1.35E-09
ErbB signaling pathway 28 / 5.05% 84 / 1.05% 2.80E-10 1.93E-09
Antigen processing and presentation 28 / 5.05% 88 / 1.10% 6.72E-10 4.45E-09
T cell receptor signaling pathway 28 / 5.05% 89 / 1.11% 8.31E-10 5.28E-09
Acute myeloid leukemia 22 / 3.97% 54 / 0.67% 1.17E-09 7.14E-09
Cytochrome P450 21 / 3.79% 52 / 0.65% 3.17E-09 1.87E-08
Adherens junction 24 / 4.33% 72 / 0.90% 5.36E-09 3.04E-08
VEGF signaling pathway 23 / 4.15% 67 / 0.83% 7.09E-09 3.89E-08
TGF-beta signaling pathway 26 / 4.69% 87 / 1.08% 8.21E-09 4.35E-08
Insulin signaling pathway 32 / 5.78% 132 / 1.64% 1.20E-08 6.18E-08
Thyroid Cancer 15 / 2.71% 29 / 0.36% 4.63E-08 2.30E-07
Fc epsilon RI signaling pathway 22 / 3.97% 70 / 0.87% 5.58E-08 2.69E-07
Notch signaling pathway 18 / 3.25% 47 / 0.59% 8.21E-08 3.84E-07
Hematopoietic cell lineage 23 / 4.15% 81 / 1.01% 1.31E-07 5.97E-07
Cell adhesion molecules (CAMs) 42 / 7.58% 242 / 3.01% 2.96E-07 1.31E-06
Type II diabetes mellitus 16 / 2.89% 41 / 0.51% 3.53E-07 1.52E-06
Alzheimer's disease 12 / 2.17% 21 / 0.26% 4.69E-07 1.96E-06
ABC transporters 16 / 2.89% 44 / 0.55% 7.61E-07 3.10E-06
Jak-STAT signaling pathway 17 / 3.07% 56 / 0.70% 2.71E-06 1.08E-05
Epithelial cell signaling in Helicobacter pylori infection 18 / 3.25% 65 / 0.81% 4.12E-06 1.60E-05
Huntington's disease 12 / 2.17% 29 / 0.36% 6.48E-06 2.45E-05
Dorso-ventral axis formation 11 / 1.99% 24 / 0.30% 7.34E-06 2.72E-05
mTOR signaling pathway 15 / 2.71% 48 / 0.60% 7.82E-06 2.83E-05
GnRH signaling pathway 21 / 3.79% 94 / 1.17% 1.19E-05 4.20E-05
Cell cycle 23 / 4.15% 115 / 1.43% 2.19E-05 7.58E-05
Protein kinases 57 / 10.29% 463 / 5.76% 4.46E-05 1.51E-04
Leukocyte transendothelial migration 22 / 3.97% 113 / 1.41% 4.71E-05 1.56E-04
p53 signaling pathway 16 / 2.89% 65 / 0.81% 4.81E-05 1.56E-04
Gap junction 20 / 3.61% 98 / 1.22% 5.85E-05 1.86E-04
PPAR signaling pathway 16 / 2.89% 68 / 0.85% 7.63E-05 2.38E-04
Melanogenesis 20 / 3.61% 101 / 1.26% 8.42E-05 2.57E-04
Progesterone-mediated oocyte maturation 20 / 3.61% 103 / 1.28% 1.07E-04 3.20E-04
Wnt signaling pathway 25 / 4.51% 149 / 1.86% 1.24E-04 3.67E-04
Linoleic acid metabolism 10 / 1.81% 31 / 0.39% 2.09E-04 6.03E-04
Long-term potentiation 15 / 2.71% 69 / 0.86% 2.69E-04 7.63E-04
Androgen and estrogen metabolism 13 / 2.35% 54 / 0.67% 2.93E-04 8.17E-04
Porphyrin and chlorophyll metabolism 11 / 1.99% 41 / 0.51% 3.90E-04 1.07E-03
Regulation of actin cytoskeleton 30 / 5.42% 213 / 2.65% 4.32E-04 1.16E-03
Renin - angiotensin system 7 / 1.26% 17 / 0.21% 5.90E-04 1.56E-03
Long-term depression 15 / 2.71% 76 / 0.95% 6.55E-04 1.71E-03
Maturity onset diabetes of the young 8 / 1.44% 24 / 0.30% 7.53E-04 1.93E-03
B cell receptor signaling pathway 14 / 2.53% 69 / 0.86% 7.75E-04 1.96E-03
Pentose and glucuronate interconversions 8 / 1.44% 25 / 0.31% 9.39E-04 2.33E-03
Amyotrophic lateral sclerosis (ALS) 6 / 1.08% 15 / 0.19% 1.65E-03 4.04E-03
ECM-receptor interaction 14 / 2.53% 84 / 1.05% 3.93E-03 9.47E-03
Tight junction 18 / 3.25% 128 / 1.59% 5.89E-03 1.38E-02
Transporters 16 / 2.89% 108 / 1.34% 5.93E-03 1.38E-02
Dentatorubropallidoluysian atrophy (DRPLA) 5 / 0.90% 14 / 0.17% 5.99E-03 1.38E-02
CAM ligands 20 / 3.61% 152 / 1.89% 7.35E-03 1.66E-02
Arachidonic acid metabolism 10 / 1.81% 54 / 0.67% 7.42E-03 1.66E-02
gamma-Hexachlorocyclohexane degradation 6 / 1.08% 23 / 0.29% 9.32E-03 2.06E-02
Complement and coagulation cascades 11 / 1.99% 69 / 0.86% 1.32E-02 2.88E-02
Calcium signaling pathway 20 / 3.61% 171 / 2.13% 2.16E-02 4.64E-02

Query Genes


Cellular antigens JAG2;  PECAM1;  NOTCH4;  CD209;  IL1R1;  HLA-DRA;  HLA-DRB1;  KDR;  HLA-DRB5;  IL2RA;  HLA-DRB3;  CD27;  TLR7;  SELP;  IGF1R;  ICOS;  IGF2R;  CDH1;  HLA-G;  CTLA4;  LRP1;  HLA-E;  INSR;  CD274;  IL4R;  CD14;  CD4;  SELE;  TNFSF11;  ITGA5;  ITGA2;  TNFRSF1B;  TNFRSF1A;  ICAM3;  IL8RB;  ICAM1;  IL8RA;  IL6R;  IL6ST;  CCR5;  CCR1;  CCR2;  CCR3;  IL10RA;  LEPR;  TLR2;  CXCR3;  MAPK14;  ABCB1;  ITGB3;  HLA-DRB4;  TNFSF10;  CXCR4;  IL1R2;  PRNP;  PDCD1;  JAG1;  CD74;  ACE;  FCER2;  TLR4;  VCAM1;  MICB;  MICA;  SIRPA;  SELL;  FCGR2A;  ITGB2;  ITGB1;  CD44;  HLA-DQB1;  FCGR3B;  FCGR3A;  ITGAL;  ITGAV;  ITGAM;  MET;  ENG;  HLA-DPA1;  CD40;  HLA-DMA;  HLA-A;  HLA-B;  HLA-C;  ABCG2;  MME;  ENPP1;  FOXP3;  TLR5;  TLR9;  ADAM17;  TNFRSF10B;  DPP4;  CD36;  HLA-DQA2;  HLA-DQA1;  HLA-DPB1;  CD86;  CD28;  CD80;  FASLG;  FAS;  NOD2;  TLR8;  NOTCH3;  NOTCH2;  NOTCH1;  
Cytokine-cytokine receptor interaction IL12B;  IL12A;  IL19;  IL13;  TNFSF11;  TNFSF10;  PRL;  CXCR4;  CXCL12;  IL6R;  TNFRSF1B;  TNFRSF1A;  CCR2;  CD40;  IL1R1;  IL1B;  IL1A;  CCL2;  CCL3;  IFNG;  IL8;  KDR;  LTA;  IL2RA;  IL2;  CX3CR1;  LEPR;  CD27;  GH1;  BMP2;  LIF;  TGFB1;  HGF;  CCR5;  CCL11;  CCL4;  CCR1;  IL18;  IL10;  IL10RA;  CNTF;  CXCL1;  LEP;  OSM;  PRLR;  CXCL10;  IL8RB;  EGFR;  EGF;  TGFB3;  TGFB2;  CCL5;  TNF;  MET;  TNFRSF10B;  IL3;  CSF2;  PDGFB;  IL4R;  IL5;  IL4;  TGFBR2;  IL6;  IL1R2;  FASLG;  FAS;  TGFBR1;  IL17A;  VEGFA;  ACVRL1;  IL6ST;  CCR3;  CXCR3;  IL8RA;  GHR;  
Prostate cancer PDPK1;  CCND1;  CHUK;  BCL2;  BAD;  PIK3CG;  PDGFB;  INS;  HSP90AA1;  MAP2K1;  RELA;  TGFA;  FOXO1;  PTEN;  IKBKB;  GRB2;  AKT3;  IGF1;  RB1;  EP300;  AKT2;  AR;  AKT1;  IGF1R;  GSK3B;  MDM2;  EGFR;  RAF1;  EGF;  TCF7L2;  E2F1;  CTNNB1;  NFKBIA;  MAPK1;  MAP2K2;  CDKN1B;  CDKN1A;  MAPK3;  CASP9;  SRD5A2;  KLK3;  KRAS;  CREB1;  CREBBP;  ERBB2;  
Toll-like receptor signaling pathway IL12B;  IL12A;  IL8;  AKT3;  CHUK;  PIK3CG;  MAP2K2;  MAP2K1;  JUN;  IRAK1;  TIRAP;  MYD88;  TLR2;  IL1B;  IKBKB;  CD14;  CCL3;  MAP2K4;  TLR4;  TLR7;  AKT1;  CD40;  AKT2;  CXCL10;  TLR5;  MAP3K7;  MAPK3;  TNF;  NFKBIA;  RAC1;  MAPK14;  MAPK1;  CASP8;  CCL4;  MAPK8;  IL6;  CD86;  CD80;  TRAF6;  TLR9;  FOS;  TLR8;  RELA;  SPP1;  
Pancreatic cancer CCND1;  CHUK;  SMAD2;  SMAD3;  SMAD4;  PIK3CG;  MAP2K1;  TGFA;  RAD51;  IKBKB;  AKT3;  RB1;  BCL2L1;  AKT1;  BRCA2;  CDC42;  EGFR;  RAF1;  EGF;  TGFB3;  TGFB2;  E2F1;  TGFBR2;  CASP9;  RAC1;  MAPK3;  MAPK1;  MAPK8;  ERBB2;  CDKN2A;  AKT2;  TGFBR1;  KRAS;  VEGFA;  RELA;  BAD;  TGFB1;  
Type I diabetes mellitus IL12B;  IL12A;  HLA-DPA1;  INS;  LTA;  IL2;  IL1B;  IL1A;  HLA-DRA;  HLA-DRB1;  IFNG;  HLA-C;  HLA-DRB4;  HLA-DRB5;  HLA-DRB3;  HLA-G;  HLA-E;  HLA-DMA;  TNF;  HLA-DQB1;  HLA-DQA2;  HLA-DQA1;  HLA-DPB1;  CD86;  CD28;  CD80;  FASLG;  FAS;  HLA-A;  HLA-B;  
Colorectal cancer CCND1;  TGFB3;  SMAD2;  SMAD3;  SMAD4;  PIK3CG;  RHOA;  BIRC5;  MAP2K1;  JUN;  AKT3;  CASP3;  GRB2;  BCL2;  BAD;  AKT1;  BAX;  IGF1R;  GSK3B;  EGFR;  RAF1;  TGFB1;  TCF7L2;  MYC;  CTNNB1;  MET;  TGFBR2;  MAPK1;  MAPK3;  CASP9;  MAPK8;  AKT2;  TGFBR1;  KRAS;  FOS;  TGFB2;  RAC1;  
MAPK signaling pathway TGFB1;  BDNF;  CHUK;  MAPK8;  PDGFB;  MAP2K2;  MAP2K1;  MAP2K5;  JUN;  GSTM3;  AKT3;  NR4A1;  GSTM1;  HSPA1B;  TNFRSF1A;  CASP3;  IL1A;  IKBKB;  RPS6KA1;  MAP2K4;  TGFB2;  HSPA1A;  MAP3K7;  FGF2;  ARRB2;  CDC25B;  MAP3K5;  AKT1;  AKT2;  EGFR;  RPS6KA5;  CDC42;  TRAF6;  RAF1;  EGF;  TGFB3;  MYC;  MAPK3;  TNF;  JUND;  GSTP1;  TGFBR2;  GSTT1;  IL1R1;  DUSP6;  MAPK14;  MAPK1;  PRKCB1;  PRKCA;  DUSP1;  GRB2;  DDIT3;  IL1R2;  MAPT;  FASLG;  FAS;  RPS6KA3;  KRAS;  CD14;  FOS;  ATF2;  RAC1;  TRAF2;  IL1B;  
Chronic myeloid leukemia CCND1;  CHUK;  SMAD4;  PIK3CG;  TGFB2;  MAP2K2;  MAP2K1;  HDAC2;  HDAC1;  AKT3;  IKBKB;  GRB2;  SHC1;  RB1;  BAD;  BCL2L1;  AKT1;  AKT2;  MDM2;  TGFBR1;  RAF1;  TGFB1;  TGFB3;  MYC;  E2F1;  TGFBR2;  NFKBIA;  CDKN1A;  MAPK3;  MAPK1;  CDKN2A;  KRAS;  RELA;  
Glioma CCND1;  SHC1;  PIK3CG;  PDGFB;  MAP2K2;  MAP2K1;  TGFA;  PTEN;  GRB2;  AKT3;  IGF1;  RB1;  AKT2;  AKT1;  IGF1R;  MDM2;  EGFR;  RAF1;  EGF;  E2F1;  CDKN1A;  MAPK3;  MAPK1;  PRKCB1;  PRKCA;  CDKN2A;  CALM3;  KRAS;  CALM1;  CALM2;  
Non-small cell lung cancer PDPK1;  CCND1;  BAD;  PIK3CG;  MAP2K2;  MAP2K1;  TGFA;  GRB2;  AKT3;  RB1;  AKT1;  AKT2;  EGFR;  RAF1;  EGF;  E2F1;  MAPK1;  MAPK3;  CASP9;  PRKCB1;  PRKCA;  ERBB2;  CDKN2A;  RXRG;  KRAS;  RXRB;  RXRA;  
Focal adhesion PDPK1;  CCND1;  BCL2;  BAD;  PIK3CG;  PDGFB;  IGF1;  MAP2K1;  ITGA5;  PTK2;  AKT3;  JUN;  PTEN;  CAV1;  VWF;  GRB2;  ITGB3;  KDR;  THBS1;  CTNNB1;  CAV2;  HGF;  AKT1;  IGF1R;  GSK3B;  CDC42;  CAV3;  COL1A1;  EGFR;  RAF1;  EGF;  RHOA;  COL3A1;  SRC;  MET;  FN1;  ITGB1;  MAPK3;  MAPK1;  PRKCB1;  PRKCA;  MAPK8;  SHC1;  ITGAV;  AKT2;  VEGFA;  ITGA2;  RAC1;  ERBB2;  SPP1;  
Adipocytokine signaling pathway JAK2;  AKT3;  CHUK;  TNFRSF1B;  TNFRSF1A;  IKBKB;  PPARGC1A;  PRKAA1;  LEP;  IRS1;  AKT1;  LEPR;  ADIPOQ;  PPARA;  TNF;  SOCS3;  NFKBIA;  STK11;  CD36;  POMC;  IRS2;  MAPK8;  AKT2;  RXRG;  RELA;  RXRB;  RXRA;  TRAF2;  
Apoptosis AKT3;  CHUK;  BCL2;  BAD;  PIK3CG;  TNFSF10;  IRAK1;  TNFRSF1A;  MYD88;  IL1R1;  CASP3;  IL1A;  IKBKB;  BID;  BCL2L1;  DFFA;  AKT1;  BAX;  AKT2;  IL1B;  TNF;  TNFRSF10B;  NFKBIA;  IL3;  CASP9;  CASP8;  FASLG;  FAS;  CFLAR;  RELA;  TRAF2;  
Bladder cancer CCND1;  MAP2K2;  MAP2K1;  IL8;  RB1;  MMP1;  MMP2;  MMP9;  CDH1;  MDM2;  EGFR;  RAF1;  EGF;  MYC;  E2F1;  CDKN1A;  MAPK3;  MAPK1;  CDKN2A;  KRAS;  VEGFA;  ERBB2;  
Endometrial cancer PDPK1;  AKT3;  BAD;  PIK3CG;  MAP2K2;  MAP2K1;  CCND1;  GSK3B;  PTEN;  GRB2;  AKT1;  AKT2;  CDH1;  EGFR;  RAF1;  EGF;  TCF7L2;  MYC;  CTNNB1;  MAPK1;  MAPK3;  CASP9;  KRAS;  ERBB2;  
Natural killer cell mediated cytotoxicity PIK3CG;  TNFSF10;  MAP2K2;  MAP2K1;  GRB2;  CASP3;  ICAM1;  FCER1G;  HLA-A;  IFNG;  HLA-C;  KIR3DL1;  MICB;  MICA;  BID;  LCK;  HLA-G;  NFATC1;  NFATC2;  HLA-E;  TNF;  TNFRSF10B;  MAPK1;  CSF2;  ITGB2;  MAPK3;  FCGR3B;  PRKCB1;  PRKCA;  ITGAL;  FCGR3A;  SHC1;  FASLG;  FAS;  KRAS;  RAF1;  RAC1;  HLA-B;  
Melanoma CCND1;  BAD;  PIK3CG;  PDGFB;  MAP2K2;  MAP2K1;  AKT3;  PTEN;  IGF1;  RB1;  AKT2;  FGF2;  HGF;  AKT1;  IGF1R;  CDH1;  MDM2;  EGFR;  RAF1;  EGF;  E2F1;  MET;  CDKN1A;  MAPK3;  MAPK1;  CDKN2A;  KRAS;  
Renal cell carcinoma AKT3;  PIK3CG;  MAP2K2;  MAP2K1;  TGFA;  GRB2;  GAB1;  ARNT;  EP300;  HGF;  AKT1;  AKT2;  CDC42;  RAF1;  TGFB1;  TGFB3;  TGFB2;  JUN;  MET;  CREBBP;  MAPK3;  MAPK1;  HIF1A;  KRAS;  VEGFA;  RAC1;  
Small cell lung cancer CCND1;  CHUK;  BCL2;  BCL2L1;  PIK3CG;  PTK2;  AKT3;  PTEN;  IKBKB;  RB1;  NOS3;  NOS1;  NOS2A;  AKT1;  AKT2;  MYC;  E2F1;  NFKBIA;  CASP9;  ITGB1;  FN1;  ITGAV;  TRAF6;  RXRG;  ITGA2;  RELA;  RXRB;  RXRA;  TRAF2;  
Metabolism of xenobiotics by cytochrome P450 UGT1A9;  GSTM3;  GSTM1;  CYP1A2;  EPHX1;  CYP1A1;  UGT2B4;  UGT2B7;  UGT2B15;  UGT2B17;  UGT1A6;  UGT1A1;  CYP1B1;  ADH1B;  GSTP1;  GSTT1;  CYP3A7;  CYP2B6;  CYP2C19;  CYP2C9;  CYP2C8;  CYP3A43;  UGT1A7;  CYP2E1;  CYP3A5;  CYP3A4;  
Cytokines IL12B;  IL12A;  BDNF;  IL13;  TNFSF11;  TNFSF10;  IGF1;  CXCL12;  IL19;  IL1RN;  IL1B;  IL1A;  CCL2;  CCL3;  IFNG;  IL8;  LTA;  IL2;  GH1;  BMP2;  LIF;  FGF2;  HGF;  CCL11;  CCL4;  IL18;  IL10;  CNTF;  CXCL1;  LEP;  OSM;  CXCL10;  EGF;  TGFB3;  TGFB2;  TNF;  IL3;  CSF2;  PDGFB;  CCL5;  IL5;  IL4;  IL6;  PRL;  FASLG;  IL17A;  VEGFA;  TGFB1;  
ErbB signaling pathway AKT3;  BAD;  PIK3CG;  MAP2K2;  MAP2K1;  PTK2;  TGFA;  GRB2;  GAB1;  MAP2K4;  AKT1;  AKT2;  GSK3B;  EGFR;  RAF1;  EGF;  MYC;  JUN;  SRC;  CDKN1A;  MAPK3;  MAPK1;  PRKCB1;  PRKCA;  MAPK8;  SHC1;  KRAS;  ERBB2;  
Antigen processing and presentation LTA;  HSP90AA1;  TAP1;  HSPA1B;  HSPA1A;  HLA-DMA;  CD74;  HLA-DRA;  HLA-DRB1;  HLA-B;  HLA-C;  HLA-DRB4;  HLA-DRB5;  HLA-DRB3;  KIR3DL1;  B2M;  HLA-G;  HLA-E;  TAP2;  HLA-DQB1;  HLA-DQA2;  HLA-DQA1;  HLA-DPB1;  HLA-DPA1;  HLA-A;  CD4;  CREB1;  CANX;  
T cell receptor signaling pathway AKT3;  CHUK;  PIK3CG;  PDCD1;  AKT1;  IKBKB;  GRB2;  IFNG;  IL2;  IL10;  AKT2;  ICOS;  CDC42;  LCK;  CTLA4;  NFATC1;  NFATC2;  RHOA;  JUN;  TNF;  NFKBIA;  CSF2;  IL5;  IL4;  CD28;  KRAS;  CD4;  FOS;  
Acute myeloid leukemia CCND1;  CHUK;  BAD;  PIK3CG;  MAP2K2;  MAP2K1;  AKT3;  IKBKB;  GRB2;  PML;  AKT1;  AKT2;  RAF1;  TCF7L2;  MYC;  PPARD;  ZBTB16;  MAPK3;  MAPK1;  KRAS;  RARA;  RELA;  
Cytochrome P450 CYP3A7;  CYP19A1;  CYP1B1;  CYP2B6;  CYP1A1;  CYP2C19;  CYP2C9;  CYP2C8;  CYP7A1;  CYP17A1;  CYP1A2;  CYP3A43;  CYP46A1;  CYP27B1;  CYP24A1;  CYP2A6;  CYP2J2;  CYP2E1;  CYP3A4;  CYP3A5;  CYP2D6;  
Adherens junction TGFBR1;  SMAD2;  SMAD3;  SMAD4;  MET;  EP300;  MAP3K7;  IGF1R;  CDH1;  CDC42;  EGFR;  TCF7L2;  RHOA;  CTNNB1;  SRC;  INSR;  TGFBR2;  RAC1;  MAPK3;  MAPK1;  CSNK2A1;  CREBBP;  ERBB2;  CSNK2A2;  
VEGF signaling pathway AKT3;  BAD;  PIK3CG;  MAP2K2;  MAP2K1;  PTK2;  KDR;  AKT1;  AKT2;  SPHK1;  CDC42;  NFATC1;  NFATC2;  MAPK3;  SRC;  MAPK1;  MAPK14;  CASP9;  PRKCB1;  PRKCA;  KRAS;  RAF1;  RAC1;  
TGF-beta signaling pathway SMAD1;  SMAD2;  SMAD3;  SMAD4;  TGFB2;  SP1;  DCN;  IFNG;  THBS1;  TGFBR2;  EP300;  BMP2;  SMAD7;  SMAD6;  SMAD5;  SMURF2;  TGFBR1;  TGFB1;  TGFB3;  MYC;  TNF;  ACVRL1;  RHOA;  MAPK3;  MAPK1;  CREBBP;  
Insulin signaling pathway PDPK1;  AKT3;  BAD;  PIK3CG;  INS;  MAP2K2;  MAP2K1;  SREBF1;  FOXO1;  IKBKB;  GRB2;  SOCS3;  PPARGC1A;  PRKAA1;  SOCS1;  IRS1;  AKT1;  AKT2;  GSK3B;  GCK;  RAF1;  INSR;  PRKCZ;  MAPK3;  MAPK1;  MAPK8;  SHC1;  IRS2;  CALM3;  KRAS;  CALM1;  CALM2;  
Thyroid Cancer CCND1;  MAPK3;  MAPK1;  PPARG;  CDH1;  MAP2K2;  MAP2K1;  NCOA4;  RXRG;  KRAS;  TCF7L2;  MYC;  CTNNB1;  RXRB;  RXRA;  
Fc epsilon RI signaling pathway AKT3;  IL13;  PIK3CG;  MAP2K2;  MAP2K1;  GRB2;  MAP2K4;  AKT1;  AKT2;  RAF1;  MAPK3;  TNF;  MAPK1;  IL3;  CSF2;  MAPK14;  IL5;  IL4;  MAPK8;  FCER1G;  KRAS;  RAC1;  
Notch signaling pathway PSEN1;  CREBBP;  NCOR2;  JAG2;  EP300;  MFNG;  NOTCH3;  JAG1;  ADAM17;  HDAC2;  HDAC1;  PSEN2;  SNW1;  NOTCH4;  PCAF;  NOTCH2;  NOTCH1;  DLL1;  
Hematopoietic cell lineage IL1R2;  ITGA2;  IL1R1;  IL1B;  IL1A;  CD14;  ITGB3;  IL6R;  IL2RA;  MME;  IL4R;  TNF;  IL3;  CSF2;  CD44;  IL5;  CD36;  IL4;  IL6;  ITGA5;  ITGAM;  FCER2;  CD4;  
Cell adhesion molecules (CAMs) PECAM1;  HLA-DPA1;  ITGA5;  ITGAV;  ITGA2;  ITGAM;  PDCD1;  CD40;  ICAM3;  HLA-DMA;  ICAM1;  HLA-DRA;  HLA-DRB1;  HLA-B;  HLA-C;  HLA-DRB4;  HLA-DRB5;  HLA-DRB3;  VCAM1;  SELP;  CD274;  ICOS;  CDH1;  HLA-G;  CTLA4;  HLA-E;  SELL;  ITGAL;  ITGB2;  ITGB1;  CD44;  HLA-DQB1;  HLA-DQA2;  HLA-DQA1;  HLA-DPB1;  CD86;  CD28;  CD80;  ITGB3;  HLA-A;  CD4;  SELE;  
Type II diabetes mellitus ABCC8;  SOCS3;  IRS1;  MAPK3;  MAPK1;  IKBKB;  KCNJ11;  MAPK8;  ADIPOQ;  PIK3CG;  GCK;  INS;  IRS2;  SOCS1;  TNF;  INSR;  
Alzheimer's disease MME;  CASP3;  SNCA;  GSK3B;  MAPT;  PSEN1;  A2M;  LRP1;  LPL;  APP;  PSEN2;  APOE;  
ABC transporters ABCC8;  ABCG2;  ABCC1;  ABCA1;  ABCC5;  ABCB4;  CFTR;  ABCB1;  TAP2;  TAP1;  ABCC3;  ABCC2;  ABCB11;  ABCG8;  ABCG5;  ABCC4;  
Jak-STAT signaling pathway JAK2;  CCND1;  AKT1;  GRB2;  STAT3;  BCL2L1;  STAT5A;  STAT5B;  STAT1;  AKT2;  EP300;  MYC;  SOCS1;  AKT3;  CREBBP;  SOCS3;  PIK3CG;  
Epithelial cell signaling in Helicobacter pylori infection RELA;  CASP3;  CHUK;  IKBKB;  MAPK8;  IL8RA;  MAP2K4;  CDC42;  IL8RB;  CSK;  EGFR;  ADAM17;  JUN;  MAPK14;  SRC;  RAC1;  MET;  NFKBIA;  
Huntington's disease CASP3;  CASP1;  CASP8;  NCOR1;  CBS;  GRB2;  CALM3;  EP300;  BDNF;  CALM1;  CREBBP;  CALM2;  
Dorso-ventral axis formation ETS1;  MAPK3;  MAPK1;  GRB2;  MAP2K1;  EGFR;  KRAS;  NOTCH4;  NOTCH3;  NOTCH2;  NOTCH1;  
mTOR signaling pathway STK11;  PDPK1;  MAPK3;  MAPK1;  AKT1;  HIF1A;  AKT2;  PIK3CG;  IGF1;  INS;  RPS6KA1;  RPS6KA3;  VEGFA;  AKT3;  PRKAA1;  
GnRH signaling pathway GNAS;  MMP2;  MAPK14;  MAPK1;  MAP2K1;  MAPK8;  MMP14;  MAP2K4;  CDC42;  MAP2K2;  KRAS;  EGFR;  CALM3;  RAF1;  PLD1;  JUN;  GRB2;  MAPK3;  CALM1;  SRC;  CALM2;  
Cell cycle PCNA;  SMAD2;  SMAD3;  CDC2;  HDAC2;  HDAC1;  CCND1;  RB1;  EP300;  SMAD4;  CDC25B;  SFN;  GSK3B;  MDM2;  TGFB1;  TGFB3;  TGFB2;  E2F1;  CDKN1B;  CDKN1A;  CDK7;  CDKN2A;  CREBBP;  
Protein kinases JAK2;  PDPK1;  GSK3B;  CHUK;  ADRBK1;  CDC2;  PRKCD;  MAP2K2;  MAP2K1;  MAP2K5;  PRKAA1;  PTK2;  IRAK1;  AKT3;  PRKCH;  IKBKB;  PRKCE;  INSR;  MAP2K4;  KDR;  PRKCQ;  TGFBR2;  TRIM24;  CSK;  CSNK2A1;  AKT2;  MAP3K5;  PDK1;  PDK2;  PDK3;  AKT1;  IGF1R;  IGF2R;  RPS6KA5;  LCK;  MAP3K7;  RAF1;  TGFBR1;  MAPK3;  SRC;  MET;  ACVRL1;  CDK9;  PRKCZ;  STK11;  MAPK14;  MAPK1;  PRKCB1;  CDK7;  MAPK8;  PRKCA;  RPS6KA1;  RPS6KA3;  PDK4;  EGFR;  ERBB2;  CSNK2A2;  
Leukocyte transendothelial migration PECAM1;  PIK3CG;  CXCR4;  CXCL12;  PTK2;  ICAM1;  VCAM1;  EZR;  MMP2;  MMP9;  CDC42;  RHOA;  CTNNB1;  ITGB2;  ITGB1;  MAPK14;  PRKCB1;  PRKCA;  ITGAL;  ITGAM;  CYBA;  RAC1;  
p53 signaling pathway PTEN;  CDKN1A;  CASP3;  CASP9;  CASP8;  BAX;  CDC2;  BID;  CDKN2A;  IGF1;  IGFBP3;  FAS;  SERPINE1;  CCND1;  MDM2;  SFN;  
Gap junction GNAS;  ADRB1;  MAPK3;  MAPK1;  PRKCB1;  DRD2;  CDC2;  PRKCA;  PDGFB;  MAP2K2;  MAP2K1;  MAP2K5;  HTR2A;  RAF1;  EGF;  GRB2;  KRAS;  SRC;  EGFR;  HTR2C;  
PPAR signaling pathway NR1H3;  MMP1;  PDPK1;  APOA5;  CD36;  APOA1;  ADIPOQ;  CYP7A1;  APOC3;  RXRG;  PPARA;  LPL;  PPARD;  PPARG;  RXRB;  RXRA;  
Melanogenesis GNAS;  MAPK3;  MC1R;  PRKCB1;  PRKCA;  POMC;  EP300;  GSK3B;  MAP2K2;  KRAS;  CALM3;  RAF1;  TCF7L2;  CREB1;  MAP2K1;  CTNNB1;  CALM1;  CREBBP;  CALM2;  MAPK1;  
Progesterone-mediated oocyte maturation AKT3;  CDC25B;  MAPK14;  MAPK1;  AKT1;  MAP2K1;  MAPK8;  IGF1R;  PIK3CG;  PGR;  IGF1;  INS;  HSP90AA1;  RPS6KA1;  KRAS;  RPS6KA3;  RAF1;  CDC2;  MAPK3;  AKT2;  
Wnt signaling pathway CCND1;  TCF7L2;  SMAD2;  SMAD3;  SMAD4;  RHOA;  PSEN1;  JUN;  EP300;  MMP7;  GSK3B;  FOSL1;  MAP3K7;  NFATC1;  NFATC2;  PPARD;  MYC;  CTNNB1;  RAC1;  PRKCB1;  PRKCA;  MAPK8;  CSNK2A1;  CREBBP;  CSNK2A2;  
Linoleic acid metabolism CYP3A7;  CYP1A2;  CYP2C19;  CYP2C9;  CYP2C8;  CYP3A43;  CYP2J2;  CYP2E1;  CYP3A5;  CYP3A4;  
Long-term potentiation MAPK3;  MAPK1;  PRKCB1;  PRKCA;  CALM3;  MAP2K2;  RPS6KA1;  KRAS;  RPS6KA3;  RAF1;  MAP2K1;  EP300;  CALM1;  CREBBP;  CALM2;  
Androgen and estrogen metabolism CYP19A1;  UGT1A6;  UGT1A9;  UGT2B4;  UGT2B7;  UGT1A1;  UGT2B15;  UGT2B17;  UGT1A7;  SRD5A2;  HSD11B1;  HSD11B2;  HSD17B1;  
Porphyrin and chlorophyll metabolism ALAD;  HMOX1;  UGT1A9;  UGT2B4;  UGT2B7;  CP;  UGT2B15;  UGT1A1;  UGT1A7;  UGT2B17;  UGT1A6;  
Regulation of actin cytoskeleton BDKRB2;  PIK3CG;  PDGFB;  INS;  MAP2K2;  MAP2K1;  ITGA5;  PTK2;  ITGA2;  ITGB3;  CSK;  EZR;  RDX;  FGF2;  CDC42;  EGFR;  RAF1;  EGF;  RHOA;  FN1;  ITGB2;  ITGB1;  MAPK3;  MAPK1;  ITGAL;  ITGAV;  ITGAM;  CD14;  KRAS;  RAC1;  
Renin - angiotensin system MME;  ACE;  CMA1;  AGT;  ACE2;  AGTR1;  REN;  
Long-term depression GNAS;  MAPK3;  MAPK1;  PRKCB1;  PRKCA;  IGF1R;  IGF1;  MAP2K2;  MAP2K1;  RAF1;  KRAS;  NOS3;  CRH;  NOS1;  NOS2A;  
Maturity onset diabetes of the young GCK;  INS;  NR5A2;  HNF1B;  HNF1A;  HNF4A;  ONECUT1;  HNF4G;  
B cell receptor signaling pathway AKT3;  CHUK;  IKBKB;  AKT2;  PIK3CG;  GSK3B;  KRAS;  NFATC1;  NFATC2;  JUN;  AKT1;  FOS;  RAC1;  NFKBIA;  
Pentose and glucuronate interconversions UGT1A9;  UGT2B4;  UGT2B7;  UGT1A1;  UGT2B15;  UGT2B17;  UGT1A7;  UGT1A6;  
Amyotrophic lateral sclerosis (ALS) CAT;  BCL2;  BAD;  SOD1;  BAX;  BCL2L1;  
ECM-receptor interaction ITGB1;  COL3A1;  CD36;  VWF;  ITGB3;  THBS1;  ITGAV;  COL1A1;  ITGA5;  ITGA2;  CD44;  GP6;  SPP1;  FN1;  
Tight junction PRKCZ;  PTEN;  AKT3;  PRKCH;  PRKCB1;  PRKCA;  AKT2;  PRKCE;  PRKCD;  CDC42;  PRKCQ;  CSNK2A1;  KRAS;  RHOA;  AKT1;  CTNNB1;  SRC;  CSNK2A2;  
Transporters ABCC8;  ABCG2;  ABCC1;  ABCA1;  ABCC5;  ABCB4;  CFTR;  ABCB1;  TAP2;  TAP1;  ABCC3;  ABCC2;  ABCB11;  ABCG8;  ABCG5;  ABCC4;  
Dentatorubropallidoluysian atrophy (DRPLA) INSR;  INS;  CASP3;  CASP1;  CASP8;  
CAM ligands MMP1;  MMP2;  COL3A1;  FN1;  VWF;  PDGFB;  THBS1;  LCK;  CTGF;  FGF2;  ADAM17;  VEGFA;  TGFB3;  TGFB2;  FGB;  COL1A1;  FGG;  SPP1;  TGFB1;  HGF;  
Arachidonic acid metabolism CYP2B6;  CYP2C19;  CYP2C9;  CYP2C8;  PTGS1;  PTGS2;  ALOX12;  PTGES;  CYP2J2;  CYP2E1;  
gamma-Hexachlorocyclohexane degradation CYP3A7;  CYP3A43;  PON1;  PON2;  CYP3A5;  CYP3A4;  
Complement and coagulation cascades MBL2;  SERPINA1;  VWF;  BDKRB2;  F7;  A2M;  FGB;  SERPINE1;  FGG;  PLAU;  SERPINF2;  
Calcium signaling pathway GNAS;  NOS3;  ADRB1;  ADRB3;  ADRB2;  PRKCB1;  PRKCA;  BDKRB2;  SPHK1;  HTR2A;  EGFR;  CALM3;  NOS1;  AGTR1;  CALM1;  NOS2A;  ERBB2;  HTR2C;  CALM2;  SLC25A4;  

Creative Commons License
© 2008-2010, Bio-X Center | Fudan University | Chinese Academy of Sciences | Shanghai Jiao Tong University
Recommended browsers: FireFox 3 or Internet Explorer 7, resolution: 1280*1024 or higher